Cell Reports
(Mar 2015)
Targeting Repulsive Guidance Molecule A to Promote Regeneration and Neuroprotection in Multiple Sclerosis
Elena Demicheva,
Yi-Fang Cui,
Philip Bardwell,
Stefan Barghorn,
Martina Kron,
Axel H. Meyer,
Martin Schmidt,
Björn Gerlach,
Mary Leddy,
Eve Barlow,
Elizabeth O’Connor,
Chee-Ho Choi,
Lili Huang,
Geertruida M. Veldman,
Horea Rus,
Alireza P. Shabanzadeh,
Nardos G. Tassew,
Philippe P. Monnier,
Thomas Müller,
Peter A. Calabresi,
Hans Schoemaker,
Bernhard K. Mueller
Affiliations
Elena Demicheva
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Yi-Fang Cui
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Philip Bardwell
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA
Stefan Barghorn
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Martina Kron
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Axel H. Meyer
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Martin Schmidt
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Björn Gerlach
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Mary Leddy
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA
Eve Barlow
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA
Elizabeth O’Connor
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA
Chee-Ho Choi
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA
Lili Huang
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA
Geertruida M. Veldman
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA
Horea Rus
Department of Neurology, School of Medicine, University of Maryland, 655 West Baltimore Street, Baltimore, MD 21201, USA
Alireza P. Shabanzadeh
Genetics and Development Division, Toronto Western Research Institute, KDT 8-418, 60 Leonard Street, Toronto, ON M5T 2S8, Canada
Nardos G. Tassew
Genetics and Development Division, Toronto Western Research Institute, KDT 8-418, 60 Leonard Street, Toronto, ON M5T 2S8, Canada
Philippe P. Monnier
Genetics and Development Division, Toronto Western Research Institute, KDT 8-418, 60 Leonard Street, Toronto, ON M5T 2S8, Canada
Thomas Müller
Department of Neurology, St. Joseph Hospital, Gartenstrasse 1, 13088 Berlin-Weißensee, Germany
Peter A. Calabresi
Department of Neurology, Johns Hopkins University, 600 North Wolfe Street, Baltimore, MD 21287, USA
Hans Schoemaker
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Bernhard K. Mueller
Neuroscience Research, Research and Development, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
DOI
https://doi.org/10.1016/j.celrep.2015.02.048
Journal volume & issue
Vol. 10,
no. 11
pp.
1887
– 1898
Abstract
Read online
Repulsive guidance molecule A (RGMa) is a potent inhibitor of neuronal regeneration and a regulator of cell death, and it plays a role in multiple sclerosis (MS). In autopsy material from progressive MS patients, RGMa was found in active and chronic lesions, as well as in normal-appearing gray and white matter, and was expressed by cellular meningeal infiltrates. Levels of soluble RGMa in the cerebrospinal fluid were decreased in progressive MS patients successfully treated with intrathecal corticosteroid triamcinolone acetonide (TCA), showing functional improvements. In vitro, RGMa monoclonal antibodies (mAbs) reversed RGMa-mediated neurite outgrowth inhibition and chemorepulsion. In animal models of CNS damage and MS, RGMa antibody stimulated regeneration and remyelination of damaged nerve fibers, accelerated functional recovery, and protected the retinal nerve fiber layer as measured by clinically relevant optic coherence tomography. These data suggest that targeting RGMa is a promising strategy to improve functional recovery in MS patients.
WeChat QR code
Close